OBIS Biotech™ · Applied biological intelligence
Understanding biology to expand biotechnology's possibilities.
OBIS Biotech™ is the biotechnology research and innovation division of OBIS Innovation & Solutions™. It connects real health needs with biological evidence, scientific intelligence and computational tools to formulate better questions—and prioritize hypotheses worthy of experimental evaluation.
Discover the vision ↓
Public Science.
Protected Innovation.
Human needBiological evidenceTestable hypotheses
01 / OBIS BIOTECH™
Institutional film · OBIS Biotech™
Science, biology and intelligence in one integrated narrative.
OBIS Biotech™ presents its scientific vision, integrated protein–genome architecture, the I²P process and the conceptual progression from LPS™ to PAK™, CMPT™ and SPI™.
Available now
02
The need before the technology
Biological complexity demands new ways to organize innovation.
Health needs do not arise as isolated problems. They unfold across a dynamic continuum of balance, vulnerability, functional disruption, damage and disease.
Knowledge remains fragmented across disciplines, databases, experimental studies and modeling tools. A relationship may appear computationally plausible and still be irrelevant in the tissue, moment or biological condition that matters. OBIS begins with the epidemiological context and the Health–Disease continuum: the need defines why we investigate; evidence suggests the path; validation decides what may advance.
The vision · Evidence first
Not to impose an answer on biology.To learn what it reveals.
Biology organizes itself through context-sensitive functions, compensatory systems, regulatory networks and adaptive responses. OBIS studies these relationships without converting coincidence into causality or plausibility into proof.
Natural intelligence, artificial intelligence, scientific literature, structural biology, protein and genomic data, and human review converge around a single purpose: to identify which signals matter, which contradictions are informative and which questions can become decisive experiments.
“The evidence suggests the rule.
The rule does not replace the evidence.”
04
One foundation · Many possibilities
A broad field of potential applications.
OBIS Biotech™ is conceived as an expansive research architecture. Its frameworks can explore biological functions and relationships across tissues, systems and states of health or disease—always through context-specific evidence and explicit prioritization.
This breadth integrates potential research programs, administration technologies, devices, biomaterials, diagnostic approaches and future biotechnology designs. It expresses the capacity of OBIS Biotech™ to explore multiple fields, establish explicit priorities and advance through evidence-guided discipline in execution.
Horizons of application
One scientific discipline.
Different health challenges.
Each field must establish its own biological context, evidence base, development pathway and validation. No area advances by analogy alone.
Respiratory & pulmonary health
The first field of execution: the interface between organism and environment, mucosal barriers and tissue protection.
Neurology
Future exploration of biological relationships relevant to carefully selected neurological needs.
Oncology
Investigation of tumor and microenvironmental contexts through independent evidence and validation.
Dentistry
Potential applications in oral health, periodontal tissues, mucosa and regenerative processes.
Veterinary medicine
A One Health perspective with research models and validation appropriate to animal health.
Veterinary dentistry
A specialized intersection of oral health, animal well-being and veterinary medicine.
Antimicrobial research
Evidence-led exploration of biological mechanisms and rational strategies for defined infectious needs.
Delivery systems
Technologies and devices for localized, contextual and scientifically justified administration.
Potential fields in human and animal health · Enabling architecture · Evidence-led · Progressively validated
06 · FIRST FIELD OF EXECUTIONRESPIRATORY &
PULMONARY HEALTH
PULMONARY HEALTH
Breathing is a continuous interface between the organism and the world.
With every breath, the respiratory tract encounters particles, microorganisms, pollutants and changing environmental conditions. Protection depends on more than airflow: epithelial integrity, mucosal defense, innate immunity, inflammation, antimicrobial activity, protease–antiprotease balance and tissue repair must remain coordinated across time.
When one or more of these protective layers become altered, vulnerability may increase and recovery may become more difficult. Infection, persistent inflammation, environmental exposure, chronic disease, aging and immunosenescence can reshape this biological context in different ways. Understanding those relationships requires an integrated view.
FIRST RESPIRATORY PLATFORMLung Protection
LPS™ / VIDGuard™
Lung Protection
Screen™
LPS™ / VIDGuard™A protective architecture inspired by natural defense.
LPS™ is the conceptual entry point of the OBIS respiratory program: a mucosal and pulmonary protection platform conceived to organize complementary biological functions at the interface where exposure, defense, inflammation and tissue integrity meet.
Its purpose is not to reproduce a single mechanism. It is to investigate whether selected protective capabilities can be coordinated within a progressively testable architecture designed around the biological context of the airway and lung.
Natural defense→LPS™→VIDGuard™
Public description at a conceptual level. The elements required to reproduce or implement the innovation—compositions, molecular relationships, formulation parameters and implementation mechanisms—remain confidential.OBIS RESPIRATORY ARCHITECTURE
From localized protection to an integrated biological response.
The program is organized as a progression of distinct platforms. Each stage expands the research question while preserving its own characterization and validation requirements.
Barrier protection
Lung Protection Screen™The initial platform investigates coordinated mucosal and pulmonary protection through complementary functions inspired by natural defenses.
Access & availability
Plasma Access Key™A proposed stage for studying how a biological architecture might extend beyond localized action and achieve broader functional availability.
Multimodal coordination
Combined Mucosal–Plasma Therapy™A conceptual architecture that combines mucosal protection and broader biological access within an integrated therapeutic response.
Systemic integration
Self-Protected Immunity™A conceptual immunological architecture that integrates protection, biological access, recognition and memory toward a resilient immune response capable of preserving its own functional integrity.
EPISTEMOLOGICAL STATUS
LPS™ → PAK™ → CMPT™ → SPI™
This sequence maps a conceptual development path; it is not a claim of efficacy, safety or clinical performance. Each platform must advance through independent structural, functional, preclinical, clinical and regulatory evaluation.
FUNCTIONAL RATIONALE
Biological functions organized for investigation.
The respiratory program begins with functions described in the scientific corpus and asks whether their relationships may support a coherent protective architecture. Their integration and therapeutic relevance require platform-specific experimental validation.
Antiprotease
Investigation of protease modulation in tissue degradation, inflammatory imbalance and pulmonary injury.
Antielastase
Investigation of protective relationships relevant to elastase activity and structural pulmonary integrity.
Anti-inflammatory
Study of excessive inflammatory responses, resolution and the biological environment required for tissue repair.
Immunomodulatory
Pursuit of a balanced defensive response while avoiding unnecessary interference with essential immune functions.
Antimicrobial
Evaluation of endogenous defensive capabilities described against selected microorganisms and defined biological contexts.
Antiviral
Mechanistic potential requiring product-specific characterization, relevant models and direct experimental testing.
THE OBIS DIFFERENCE
The platform family is investigated through the OBIS analytical architecture.
Respiratory need defines the priority. Evidence determines which relationships deserve examination. IPF™, PMT™, SGO™ and TCM™ organize the questions that precede modeling and experimentation.
Intrinsic Protein Functions
Identifies intrinsic and context-dependent protein functions relevant to mucosal, pulmonary and systemic protection.
Protein Molecular Tuning
Examines convergence, complementarity, compensation and coordination among selected biological capabilities.
Structural Genomic Orchestration
Studies how expression, regulation and genomic organization may contextualize the proposed functional relationships.
Total Chromosomal Mapping
Maps regulatory, structural and topological patterns that may strengthen, challenge or refine respiratory hypotheses.
WHY THIS FIELD FIRST
A place where need, biological complexity and translational possibility converge.
OBIS Biotech™ has selected respiratory and pulmonary health as its first field of execution because it offers a clearly defined human need and a biologically rich setting in which protective systems can be studied together. The aim is to move from epidemiological priority to traceable biological questions, and from those questions to hypotheses that can be challenged experimentally.
Initial research programs examine protective biological architectures at the mucosal and pulmonary interfaces. Their public presentation remains institutional and conceptual: proprietary designs, enabling parameters, formulations and unvalidated mechanisms remain protected.
Respiratory and pulmonary health is the first field of execution—not the limit of the OBIS Biotech™ architecture.LPS™ / VIDGuard™PAK™CMPT™SPI™Mucosal protectionPulmonary protectionFunctional coordinationProgressive validation
From need to translation
Every advance must preserve the complete history of the scientific decision.
OBIS organizes research as a traceable sequence. No tool, prediction or intuition replaces the evidence required at each stage.
- 01
Define the health need and its place within the Health–Disease continuum.
- 02
Gather and classify relevant evidence, including contradictions and negative findings.
- 03
Identify protein functions and biological relationships worthy of examination.
- 04
Integrate genomic, regulatory, chromosomal, tissue and temporal context.
- 05
Formulate explicit, testable hypotheses that remain open to refutation.
- 06
Model and prioritize without confusing prediction with demonstration.
- 07
Design structural, biophysical, functional and safety studies.
- 08
Advance toward translation only when accumulated evidence justifies it.
The scientific architecture organizes decisions. Experimentation determines whether a hypothesis deserves to progress.
The scientific enabling core
Before asking how molecules interact, we ask which relationships are relevant.
OBIS Integrated Protein–Genome Intelligence Platform™ connects epidemiological need, disease biology, protein function, molecular relationships, gene expression, regulation, chromosomal organization, scientific literature and artificial intelligence.
Its role is to transform dispersed knowledge into traceable, prioritized hypotheses. It does not replace structural or experimental tools; it seeks to formulate better questions for them and reintegrate their results into a continuous cycle of challenge and review.
OBISIntegration
EpidemiologyDisease biologyProtein functionGene expressionGenomic regulationChromosomal architectureStructural biologyScientific literatureThe analytical architecture
Four layers.
One evidence-first system.
Each framework asks a different question. Together they extend inquiry from molecular function to protein–genome context—without confusing convergence with proof.
01IPF™
Intrinsic Protein Functions
What can a protein do in a specific biological context?Characterizes intrinsic and context-dependent functions across tissue, state, modification and condition.
02PMT™
Protein Molecular Tuning
Which functional relationships deserve investigation?Examines convergence, complementarity, compensation, regulation and functional uncoupling.
03SGO™
Structural Genomic Orchestration
How might genomic organization contribute?Studies shared regulation, expression and genomic architecture without assuming automatic causality.
04TCM™
Total Chromosomal Mapping
What patterns emerge at chromosome and genome scale?Maps functional, regulatory, structural and topological layers to generate testable hypotheses.
NEEDEVIDENCEIPF™PMT™SGO™TCM™VALIDATION
From hypothesis to validation
Convergence increases priority.
Reality decides.
Modelable does not mean true. Plausible does not mean demonstrated. OBIS distinguishes association, structural plausibility, functional activity, causality, safety and clinical relevance because each level requires its own evidence.
01
Hypothesis
An examinable proposition derived from evidence and explicit reasoning.
02
Modeling
Computational assessment that orients, prioritizes and generates predictions.
03
Validation
Experimental challenge through controls, replication and defined criteria.
Prediction is not proof.Correlation is not causality.Experimental validation remains decisive.
OBIS Integrated Protein–Genome Intelligence Platform™
This synthesis article develops the scientific and conceptual foundation of the OBIS Integrated Protein–Genome Intelligence Platform™ and presents its evidence-guided prioritization architecture—from identifying relevant biological relationships to formulating hypotheses and their experimental validation.
Read & download PDF →Collaboration and a shared future
Better questions create better possibilities.
OBIS Biotech™ seeks relationships with scientists, academic institutions, health organizations, pharmaceutical and biotechnology companies, artificial-intelligence developers, modeling specialists, investors and partners capable of contributing to rigorous evaluation.
Collaboration may begin through scientific exchange, external review, pilot definition, access to technological capabilities, experimental design, independent validation or joint development—always according to maturity and the appropriate confidentiality framework.
It is not human intelligence replaced by artificial intelligence. It is intelligence working with intelligence.
I²P collaborative process
Intelligence working
with intelligence.
Human intelligence defines purpose, weighs context and assumes responsibility. Artificial intelligence expands synthesis, representation and analytical reach. Neither replaces evidence—and neither replaces experimental truth.
HIHuman intelligence
I²PPurpose · Judgment
Context · Responsibility
AIArtificial intelligence
Synthesis · Structure
Analysis · Scale
Conceptual publication · I²P
OBIS
Cognition™
An epistemological architecture for interintelligent, recursive and traceable production.
Conceptual article
Human-AI Triangulation for Knowledge Production
From collaborative intelligence to verifiable production.
A conceptual article from OBIS Cognition™ that develops human-AI triangulation as an operational architecture within I²P. The document describes how human intelligence, Chat and Work (ChatGPT, OpenAI) can perform differentiated functions of conceptualization, development, contrast, review and authorization within an interintelligent, recursive and traceable process.
Read & download the article →Scientific transparency
Clear about authorship.
Precise about limits.
IPF™, PMT™, SGO™ and TCM™ are concepts and architectures developed by OBIS Innovation & Solutions™ through I²P, a collaborative process assisted by ChatGPT, an artificial intelligence system developed by OpenAI. Scientific review, adoption, application and final responsibility rest exclusively with OBIS Innovation & Solutions™.
Public scienceScientific philosophy · Definitions · Evidence-first architecture · Validation principlesProtected innovationMolecular designs · Formulations · Sequences · Protocols · Patent-sensitive embodiments
The concepts, platforms, programs and fields described are at different stages of development. Their inclusion does not constitute a claim of efficacy, safety, regulatory approval, commercial availability or clinical superiority.
The vision
From evidence
to biotechnology.
Experiments answer questions.
Reality decides.